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Abstract: Limited reproducibility of preclinical data is increasingly discussed in the literature. Failure of drug devel-
opment programs due to lack of clinical efficacy is also of growing concern. The two phenomena may share an impor-
tant root cause — a lack of robustness in preclinical research. Such a lack of robustness can be a relevant cause of fail-
ure in translating preclinical findings into clinical efficacy and hence attrition, and exaggerated cost in drug develop-
ment. Apart from the study design and data analysis factors (e.g., insufficient sample sizes, failure to implement blind-
ing, and randomization), heterogeneity among experimental models (e.g., animal strains) and the conditions of the study 
used between different laboratories is a major contributor to the lacking of robustness of research findings. The flipside 
of this coin is that the understanding of the causes of heterogeneity across experimental models may lead to the identi-
fication of relevant factors for defining the responder populations. Thus, this heterogeneity within preclinical find-
ings could be an asset, rather than an obstacle, for precision medicine. To enable this paradigm shift, several steps need 
to be taken to identify conditions under which drugs do not work. An improved granularity in the reporting of preclini-
cal studies is central among them (i.e., details about the study design, experimental conditions, quality of tools and rea-
gents, validation of assay conditions, etc.). These actions need to be discussed jointly by the research communities in-
terested in preclinical data robustness and precision medicine. Thus, we propose that a lack of robustness due to the 
heterogeneity across models and conditions of the study is not necessarily a liability for biomedical research but can be 
transformed into an asset of precision medicine. 
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Introduction 
rivate and public investment in fundamental 
biomedical research continues to be strong; con 
comitantly, biomedical researchers now have 
more sophisticated tools at hand than ever before. 
This combination should offer unparalleled opportuni-
ties for the discovery and development of new and  
potentially transformative therapeutics. However, the 
overall productivity of drug research and development, 
i.e., the number of new therapeutics developed per 
dollar invested, has nonetheless significantly declined 
over the past several decades[1]. One driver of low 
productivity is the increasing cost of drug develop-
ment that is itself driven, for example, by increasing 
demands from regulatory authorities and health tech-
nology assessment bodies. A possibly even bigger cost 
driver is (late stage) attrition[2]. Attrition rates in 
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the clinical phase remain high[3], and lack of efficacy 
has become the most important reason for attrition[4]. 
There may be a number of reasons for the failure to 
translate promising preclinical data into clinical effi-
cacy[5,6]. Animal models of disease are the corner-
stones of drug development[7] but in many cases 
have been insufficiently validated for being predictive 
of efficacy in patients[8,9]. Moreover, potential thera-
peutic targets, which are in part derived from such 
models, may have been insufficiently validated[10].  
Limited validation of both animal models and pro-
posed drug targets appears to be at least partly related 
to a lack of reproducibility of preclinical data[11,12]. 
Accordingly, this lack of reproducibility has become a 
major concern for funding agencies such as the Na-
tional Institute of Health (NIH)[13]. For drug discovery 
and development, failure to reproduce research find-
ings may result in longer drug research and develop-
ment times, thereby leading to increased costs[14], ab-
andoning of research programs and, as a financial and 
ethical worst case, to lack of efficacy in clinical proof- 
of-concept studies. Concerns about the reproducibility 
of preclinical data have triggered discussions around 
various aspects of good research practice such as 
transparent data analysis[15,16], reporting on the use of 
laboratory animals[17], and reassessment of data pub-
lication guidelines by the peer-reviewed literature ve-
nues[18]. 
While the lack of reproducibility is not the only 
factor leading to poor prediction of clinical effica-
cy based on preclinical data[19], addressing it is critical 
for restoring the self-correcting nature of science[20]. 
In this review, we argue that certain cases of what 
is called as “lack of data reproducibility” could be con-
verted into exciting discoveries leading to innovative 
personalized medicine. 
Data Reproducibility vs Robustness 
Given that the term “reproducibility” itself has caused 
quite a lot of confusion, it therefore needs to be de-
fined. It has been suggested that the follow-up expe-
riments for an initial set of data fall into one of 
two categories — replication or robustness tests[21] 
(Table 1). Replication follow-up tests are conducted 
using the same methods and population as the original 
study, and usually meant to evaluate measurement 
error. Replication tests use the same sampling distri-
bution for parameter estimates; therefore, reduce 
the conditions for discrepancy result from random ch-
ance, error, or inappropriate handling of data (Table 1). 
In contrast, robustness tests are conducted using dif-
ferent methods or on a new sample drawn from a dif-
ferent population (Table 1) and evaluate the generali-
zability of research findings. Evaluation of the genera-
lizability of the phenomenon allows a result to be as-
sessed based on differences between testers under dif-
ferent conditions and sampling distributions. In prec-
linical drug research and development, discussions of 
“reproducibility” have focused nearly exclusively on 
tests of robustness. Therefore, in the subsequent dis-
cussion, we refer to the robustness of preclinical data 
rather than “reproducibility”. 
 
Figure 1. A proposed definition to distinguish replication and robustness tests. 
 
*Reproduced from[21] with permission. 
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Data Robustness from the Generalizability 
Perspective 
Most research groups in academia and industry have 
their preferred protocols, suppliers of tools, reagents 
and cell lines or animals and, in clinical research, pre-
ferred sources and types of study subjects. These fac-
tors are dictated by a number of budgetary, logistic, 
historical, and other practical considerations. They 
help to standardize methods and test conditions within 
a laboratory. Thereby, they have a positive impact on 
the “local” (within-laboratory) probability of success 
of a research project, as reflected by the outcome of 
statistical analyses (i.e., standardization efforts are 
aimed at achieving “statistical generalizability”[22]). 
However, they may reduce the probability that other 
investigators, applying minor variations of a protocol, 
and performing the same experiments at a different 
location with that location’s preferred standards, and 
obtain the same result. While multi-center trials ap-
plying a standardized protocol have become the ben-
chmark in clinical research, their application to prec-
linical research is only slowly emerging[23]. 
This uniqueness of each research environment ma-
kes the comparisons between results generated across 
laboratories very important. Seen from the perspective 
of the development of drugs for typically highly hete-
rogeneous patient populations, it is probable that data 
generated by one laboratory is more likely to be suc-
cessfully translated when similar findings are also 
obtained under the disparate conditions of other labor-
atories; thus, establishing the generalizability of the 
results (“scientific generalizability”[22]). 
The sensitivity of preclinical assays for a given 
pharmacological target often depends on assay condi-
tions. This could bias a project work towards having 
positive results if careful benchmarking is not per-
formed. Therefore, it is essential that methods for de-
fining data generalizability are put into practice. The 
guiding assumption for this is that the broader the 
range of circumstances and laboratory environments 
in which preclinical efficacy can be demonstrated, the 
higher the likelihood of detecting efficacy signals in 
the clinical studies that include a broad spectrum of 
patients. For instance, the clinically successful anal-
gesic morphine anxiolytic diazepam works reliably 
in both males and females of various strains and spe-
cies of laboratory animals under most, if not all, lab-
oratory conditions. The question is whether there is 
value in data that can be generated only under cer-
tain conditions (e.g., in one laboratory but not in oth-
ers). In this report, we argue that, in some cases, the 
apparent limited robustness of research findings may 
open the road in identifying a novel approach to per-
sonalized medicine. 
Generalizability and Precision Medicine 
The concept of personalized medicine is based on the 
heterogeneity of response to drug treatment, i.e., a 
drug may not work in all patients presented with a 
given condition. For instance, both muscarinic ace-
tylcholine receptor antagonists and β3-adrenoceptor 
agonists have been shown to be effective treatments 
for the overactive bladder syndrome; however, each of 
these two drug classes has a limited responder rate, 
and these responder populations overlap only part-
ly[24,25]. It follows that a drug effective in a subgroup 
of patients with a given disease may therefore be just 
partially effective or even ineffective when being 
tested in a broader population. Under such circums-
tances, a study may be declared as “negative,” adding 
to the mounting evidence of preclinical-to-clinical 
translation failures. 
Since the completion of the Human Genome Pro-
ject, major advances in genome technology have led 
to an exponential decrease in sequencing costs[1]. In 
some areas of medicine, patients have benefited from 
the development of new drugs with labels that now 
include pharmacogenomic information. Patients with 
melanoma, leukemia, or metastatic lung, breast, or br-
ain cancers are now routinely offered a “molecular 
diagnosis” (e.g., BRAF-positive melanoma; EGFR- 
positive or ALK-positive non-small cell lung cancer), 
and therefore, may receive tailored treatments that can 
greatly improve the chances of survival. 
Progress made in the cancer field is based on sig-
nificant investments into research on disease biology. 
However, there are areas of medicine, in which the 
only available alternative treatment option is when, if 
no clinical response is observed to one drug, patients 
are switched to another, and so on, following a con-
ventional trial-and-error approach. This is especially 
true for the field of psychiatry, where diagnostic cate-
gories are not based on biological mechanisms and no 
tests are available to support the diagnoses. As the 
trial-and-error approach will certainly not work for the 
development of novel drugs because clinical studies 
are too expensive and follow stringent ethical aspects, 
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one should look for other sources of information 
which may instruct the development of effective pa-
tient-centric treatments. Evidence on drug treatment 
response heterogeneity in preclinical studies may be 
one such example of information that is worth be-
ing collected and carefully analyzed. 
Limited Generalizability of Preclinical Find-
ings: Genetic Factors 
The strain or even sub-strain of laboratory animals is 
known to affect the development and expression of the 
various phenomena that are the subject of investiga-
tion in preclinical research. For instance, the inbred 
spontaneously hypertensive rat is the most frequently 
used animal model in arterial hypertension resea-
rch[26], but animals from different suppliers exhibit 
genetic and phenotypic heterogeneity[27]. Models of 
disease-like processes and conditions are frequently 
reported to require a certain strain of animals. In 
some cases, differences between strains may have an 
obvious physiological explanation (e.g., albino rats 
have compromised vision and may not be used in 
tasks dependent upon intact vision[28]). In other cases, 
differences are likely to be more complex, require 
deeper evaluation and may be very instrumental in 
developing valid disease models to study novel treat-
ment approaches. For example, Bottger and collea-
gues[29] have compared the effects of hypercholestero-
lemic diets in 12 inbred strains of rats and identified 
hyper-, normo- and hypo-responders. Similarly, the 
effects of ovariectomy on bone loss varies among 
strains of mice and this was argued to be relevant for 
the development of models for postmenopausal os-
teoporosis and preclinical testing of potential thera-
pies[30,31]. 
Since the disease models are often designed using a 
specific and often inbred strain of animal, the effects 
of drugs are much less likely to be compared between 
different strains. Nevertheless, the available examples 
suggest that drug effects may be subject to strain-dep-
endence. For example, the impact of the immunosup-
pressants cyclosporin A and tacrolimus on retinal gan-
glion cell survival and axonal regeneration appear 
to be more likely in Fischer F344 rats than in Lewis 
rats[32]. Given that it is the Lewis rats, and not the 
F344 rats, that are vulnerable to inflammatory aspects 
of autoimmune insults, the neuroprotective and rege-
nerative effects of agents such as cyclosporin A and 
tacrolimus may be of particular relevance to specific 
subpopulations of patients with autoimmune disease 
(e.g., progressive forms of multiple sclerosis). 
Evaluating the strain-dependence of the effects of 
established and investigational treatments may also 
deliver potentially useful information. For example, 
the glucocorticoid dexamethasone, the histamine H1 
receptor antagonist pyrilamine, and the novel hista-
mine H4 receptor antagonist JNJ7777120 have been  
compared in a mouse model of acute skin inflamma-
tion induced by local application of croton oil[33]. 
While dexamethasone and pyrilamine induced signif-
icant anti-inflammatory effects in CD-1 mice and 
NMRI mice, JNJ777720 was effective only in CD-1 
mice[33], a finding likely to affect the translateonal 
potential of these preclinical data in clinical settings. 
Drug safety is just as important as therapeutic effi-
cacy for precision medicine. Drug safety defines not 
only the dose range to be studied in humans but also 
the subpopulations of patients who may or may not be 
susceptible to drug’s adverse effects. However, strain- 
dependent differences in a drug’s toxicological profile 
are not addressed routinely in conventional preclinical 
safety evaluation programs. Certain findings that pre-
clude further development of a drug candidate may 
turn out to be strain-specific and of limited or absence 
of clinical relevance. For example, acrylamide is 
a commonly used industrial chemical which was sug-
gested to have carcinogenic potential based on stu-
dies conducted exclusively in the Fischer F344 rat, but 
these predictions have since been challenged by stu-
dies using other rat strains[34]. 
Although the strain of research subject may be re-
sponsible for the observation of the differences in the 
study outcome, what is far less frequently emphasized 
is that factors such as sub-strains and breeding centers 
supplying research animals could also play a role in 
the outcome of the study[27]. For example, in the mod-
el of dexamethasone-induced osteonecrosis, aside 
from the known strain-specific susceptibility dexame-
thasone treatment, there are also sub-strain-specific 
differences in the adverse effects, i.e., stronger effects 
in BALB/cJ compared with BALB/cAnNHsd[35]. If 
the name of the (sub)strain is not explicitly stated in 
the published report, inconsistencies in results be-
tween studies may sometimes be attributed to different 
suppliers of animals. For instance, Palm and col-
leagues[36] reported differences in basal and etha-
nol-induced levels of opioid peptides in Wistar rats 
from five different suppliers, but this paper does not 
identify the used strains according to suggested no-
menclature[37]. For Wistar rats in particular, this in-
formation would have been of great importance given  
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the sub-strains that were developed and maintained by 
different breeders (Figure 2), which may have 
unique behavioral and biochemical characteristics. In 
the presentation at the 2006 meeting of the Society for 
Neuroscience, Lindemann and colleagues[38] demon-
strated that one of the common Wistar rat sub-strains 
has a significantly reduced expression of metabotropic 
glutamate receptor 2 (mGlu2) and, therefore, is less 
likely to respond to mGlu2/3 receptor agonist treatment. 
Sub-strains of Wistar rats were also shown to exhibit 
heterogeneous expression of mGlu2 receptors and the 
Wistar sub-strains with reduced mGlu2 receptor ex-
pression also exhibited an anxiety phenotype[39]. As 
several compounds targeting this receptor system are 
undergoing clinical development, analysis of the he-
terogeneity of mGlu2 receptor expression among these 
rat sub-strains may be important to predict drug treat-
ment response. Accordingly, the Animal Research: 
Reporting of In Vivo Experiments (ARRIVE) guide-
lines now call for the reporting of animal species, 
strain, gender, and supplier[17]. 
Limited Generalizability of Preclinical  
Findings: Environmental Factors 
Laboratory and animal housing environments are argu-
ably the richest source of factors that may appear dif-
ficult to control; often neglected but are likely to have 
an impact on the generalizability of results obtained in 
preclinical studies. Similar to what was discussed 
above for genetic factors, analysis of environmental 
influences may also guide the development of perso-
nalized medicine. 
Environment is traditionally viewed as an important 
aspect of model development and treatment efficacy 
in psychiatry. Indeed, there is a large body of evidence 
arguing that environmental influences have a signifi-
cant impact on the performance of animal models in 
psychiatry (e.g., ventral hippocampus lesion model in 
rats[40]). Clinical research points at the combined op-
eration of genetic and environmental factors in the 
development of complex disease states such as major 
depressive disorder[41]. It is expected that these inte-
ractions delineate specific biological subtypes of de-
pression and that individuals with such pathophysio-
logical distinct types of depression will likely respond 
to different treatments[41]. 
In preclinical neuroscience, environmental factors 
are not limited to handling and housing conditions 
which may be more or less stressful for the study an-
imals and therefore, associated with the outcome of 
the study. Equally, if not more important, are infec-
tions common in animal houses. Health status is rarely 
reported in scientific publications despite the fact that 
even a subclinical infection may have a major impact 
 
 
 
Figure 2. The origins and relationships of Wistar rats available from several commercial sources. Conventional name of the strain is 
shown in the bottom row (following the information provided by the respective breeders). 
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on the outcome of preclinical studies in various fields. 
For example, in the field of neurodegenerative disord-
ers, planned and controlled experimental manipulation 
(e.g., intracerebral injection of a lesion-inducing agent) 
may run unintentionally and unknowingly concur-
rently with subclinical encephalitis due to common 
mouse virus infections (e.g., mouse hepatitis virus or 
Theiler's encephalomyelitis virus). Investigational 
treatment may work well under those conditions but 
has no impact under “cleaner” conditions. An analogy 
of this in in vitro research is the lack of reporting of 
potential mycoplasma contamination of cell lines un-
der investigation. If the reasons for differing responses 
are not known, such observations will be yet another 
example of the unreliability of preclinical science. If 
the reasons were known and understood, this could 
lead to a specific “tailored” use of the studied drug. 
Limited Generalizability of Preclinical  
Findings: The Reverse Translation Approach 
There is an overall strong bias towards publishing 
positive data. Negative data, which might be impor-
tant in the context of the current discussion, are rarely 
published and there are three main reasons for this. 
First, there is no established process to encourage dis-
closure of such data. Second, such data may often 
simply not exist because there are many factors that 
limit motivation to repeat previously published studies 
— e.g., bioethical considerations or associated costs. 
Third, authors feel that specifically high profile jour-
nals are unlikely to accept negative data. 
Therefore, there is a need to stimulate research that 
would be aimed at establishing heterogeneity of spe-
cific phenomena in preclinical research. Clinical evi-
dence of a poor or insufficient response to investiga-
tional treatment may serve this purpose (especially, in 
those cases where obvious reasons for failing preclin-
ical-to-clinical translation can be excluded). For ex-
ample, κ-opioid receptor antagonists were seen as 
potential antidepressant drugs, but clinical trial re-
sults are so far rather disappointing[42] and may pro-
mpt re-evaluation of preclinical evidence. In this vein, 
κ-opioid receptor antagonists produced antidepres-
sant-like effects in the Wistar-Kyoto but not Spra-
gue-Dawley rats, while a reference agent, the clinically 
used antidepressant desipramine, was effective in both 
strains[43]. Deeper analysis of such strain-specific ef-
fects is warranted by unsatisfactory clinical efficacy 
and may lead to the establishment of markers identi-
fying responder population (in both animals and hu-
mans).  
Another example of a novel drug, in which the re-
sults of clinical testing were disappointing, is the 
mGlu2/3 receptor agonist pomaglumetad, which was 
developed to treat schizophrenia. The Phase III pro-
gram has been halted in view of insufficient clinical 
efficacy, which was due, at least in part, to the inability 
to identify a treatment responder population[44]. As 
mentioned above, there are preclinical reports on rat 
sub-strains with reduced expression of mGlu2 receptor 
and reduced responses to mGlu2/3 receptor agonist tre-
atment[38,39]. Furthermore, it has been shown that ani-
mals with low levels of mGlu2 receptor expression in 
the brain are characterized by a higher propensity to 
drink alcohol[45], and reduced levels of mGlu2 receptor 
expression have also been noted post mortem in the 
brains of the human subjects with alcohol depen-
dence[46]. These findings need to be confirmed but it 
may well be that mGlu2 receptor expression varies 
in both animals and humans, and this may be asso-
ciated with a differential response to treatment with 
mGlu2 receptor agonists and positive allosteric mod-
ulators and, therefore, could be used to establish com-
panion diagnostics to enable the personalized use of 
this class of drugs.  
An example of successful reverse translation is the 
use of β3-adrenoceptor agonists in the treatment of 
obesity and type 2 diabetes[47]. Based largely on find-
ings in rodents, several pharmaceutical companies 
embarked on drug development programs for β3-ad-
renoceptor agonists in the 1980s. However, all of 
these programs failed. It later became clear that the 
key reason for failure was a difference in the presence 
of target tissue (brown adipose fat) and of target func-
tion (β3- vs. β1- and β2-adrenoceptor role in lipoly-
sis) between rodents and humans[47]. Moreover, this is 
also an example for the role of publication bias, as 
only one of the various failed β3-adrenoceptor agonist 
programs in obesity and type 2 diabetes has published 
its negative proof-of-concept data[48]. 
Limited Generalizability of Preclinical  
Findings: Path Forward 
In the clinic, the therapeutic response to medication is 
known to vary between patients; this is the case for 
established drugs and may be a contributing factor to 
the many failures in clinical studies of novel investi-
gational agents that have been tested without any pa-
tient stratification strategy. In contrast, preclinical re-
ports on heterogeneity in treatment response are rather 
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rare. Understanding the reasons for such a lack of in-
formation also suggests the steps that are to be taken 
to generate missing evidence. 
First, if both positive and negative data are gener-
ated in the same lab using, for example, different 
strains of animals, a report may indeed be published 
arguing for strain-dependent effects of an experimen-
tal manipulation (e.g., a drug administration). Howev-
er, if a laboratory generates negative data only, such 
results may stay unpublished, preventing the scientif-
ic community from access to this information. In an 
extreme case, a laboratory may even report only the 
positive findings on the animal strain yielding these 
positive results only, not disclosing those on the strain 
yielding the negative results. Thus, an obvious step 
to be taken is to establish a mechanism whereby nega-
tive data become shared. Several examples of such 
mechanisms include publication portals dedicated to 
negative data (e.g., F1000’s preclinical reproducibili-
ty channel[49]), pre-print archives (e.g., bioRxiv[50]), 
online forums for scientific discussions (e.g., PubMed 
Commons[51]), or information sharing portals such as 
those developed by the ECNP Preclinical Data Fo-
rum[52]. In a more general vein, positive findings in 
one animal strain and negative ones in another should 
not necessarily be seen as a limitation of a study; ra-
ther, they could be used as guidance for much more 
specifically understanding of the driving force behind 
the positive findings. Such understanding may lead to 
the identification of factors which could be used to 
identify suitable patient populations for clinical testing. 
Second, published reports often fail to include im-
portant details about the materials and methods used; 
information that may facilitate the understanding of 
the origin of discrepant findings. For example, as ar-
gued above, mentioning the exact laboratory animal 
strain nomenclature and the source may be very criti-
cal[17]. As it is difficult to establish, a priori, what in-
formation may turn out to be crucial, the study proto-
cols including all potentially relevant details (e.g., 
health reports) may eventually be required to be stored 
in online repositories and referenced in the to-be-pub-
lished work. 
Third, large collaboration projects involving inde-
pendent laboratories could provide a basis for study-
ing treatment response heterogeneity. A recent EU- 
funded initiative[53] has established web-based plat-
forms for multicenter animal studies. Another example 
is the Interventions Testing Program at the National 
Institute of Aging, which has the explicit aim of con-
firming the reported potential of treatments to extend 
lifespan, and delay disease and dysfunction under the 
most rigorous conditions — multiple test sites, spe-
cially bred genetically heterogeneous mice of both 
sexes, and very well powered[54].   
It has to be emphasized that such multi-site re-
search projects often aim at generating more robust 
findings[55] and, therefore, need to be equipped with 
additional resources and specific technologies to enable 
analysis of response heterogeneity. On the one hand, 
thanks to advances in technologies and reduced costs, 
whole-genome sequencing is no longer considered a 
technical problem, even for preclinical studies. How-
ever, computational methodologies for data analysis 
and interpretation of the functional relevance of iden-
tified genetic variants may present a challenge requir-
ing careful planning and appropriate funding[56]. For 
example, in a study conducted in 23 inbred mouse 
strains, a number of cardiovascular parameters were 
assessed after chronic administration of a β-adreno-
ceptor agonist and antagonist. Reflecting the com-
plexity of the observed patterns of effects, the conclu-
sion was that “cardiovascular phenotypes are unlikely 
to segregate according to global phylogeny, but ra-
ther be governed by smaller, local differences in the 
genetic architecture of the various strains”[57]. On the 
other hand, in order to reliably identify genomic pre-
dictors of drug response or to effectively identify a 
drug’s mechanism of action in a multi-site project, 
standardization of drug-response measurements is 
essential[58] and, if insufficient, may lead to discrepant 
observations that are too weak to support precision 
medicine. 
In conclusion, heterogeneity between models and 
experimental procedures are an important source of 
the lack of robustness of the reported research findings. 
Such unrobust data can be a relevant cause of failure 
in translating preclinical findings into clinical efficacy, 
and subsequent attrition and exaggerated cost in drug 
development. The flipside of this coin is that under-
standing of the causes of heterogeneity may lead to 
the identification of relevant factors for the identifica-
tion of responder populations. Thus, heterogeneity 
within preclinical findings, if built into study de-
sign, controlled for and evaluated effectively, may 
prove to be an asset, rather than a problem, for the 
development of precision medicine. To enable this 
paradigm shift, several steps need to be taken to iden-
tify conditions under which drugs do not work. An 
improved granularity in the reporting of preclinical 
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studies is central among them (i.e., details about study 
design, experimental conditions, quality of tools and 
reagents, validation of assay conditions, etc.). These 
actions need to be discussed jointly by preclinical data 
robustness and precision medicine research communi-
ties; emphasizing the role of collaboration in success 
strategies[59,60].  
In closing, we would like to draw attention to an 
example of how careful attention to the differenc-
es between research models may lead to important 
discoveries. The T-cell-derived S49 cell line can be 
killed by β-adrenoceptor agonists, such as isoprena-
line, and other cAMP- increasing agents, such as 
forskolin. Sub-strains of this cell line have been 
shown to be differentially sensitive to those agents[61]. 
Looking more deeply into these findings has led to the 
identification of G-proteins and adenylyl cyclases as 
parts of the cellular signal transduction machinery, and 
eventually to a Nobel Prize for Alfred G. Gilman, the 
scientist who observed and reported these differences. 
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